切换至 "中华医学电子期刊资源库"

中华肾病研究电子杂志 ›› 2015, Vol. 04 ›› Issue (04) : 192 -195. doi: 10.3877/cma.j.issn.2095-3216.2015.04.006

所属专题: 文献

专家论坛

妊娠期高血压疾病的处理
何娅妮1,(), 刘佳睿1   
  1. 1. 400042 重庆,第三军医大学大坪医院肾内科
  • 出版日期:2015-08-28
  • 通信作者: 何娅妮

Management of hypertensive disorders in pregnancy

Yani He1,(), Jiarui Liu1   

  1. 1. Department of Nephrology, Daping Hospital, Research Institute of Surgery, Third Military Medical University, Chongqing 400042, China
  • Published:2015-08-28
  • Corresponding author: Yani He
  • About author:
    Corresponding author: He Yani, Email:
引用本文:

何娅妮, 刘佳睿. 妊娠期高血压疾病的处理[J/OL]. 中华肾病研究电子杂志, 2015, 04(04): 192-195.

Yani He, Jiarui Liu. Management of hypertensive disorders in pregnancy[J/OL]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2015, 04(04): 192-195.

妊娠期高血压疾病(HDP)是妊娠期常见的以高血压、肾功能损害、神经系统症状为主要表现的严重临床综合征,是导致妊娠期死亡的首要原因。根据2013美国妇产科医师协会指南HDP可分为妊娠期高血压、子痫前期-子痫、慢性高血压及慢性高血压并发子痫前期。妊娠期血压≥160/110 mmHg应给予降压治疗。钙离子拮抗剂、交感神经抑制剂应作为降压药物的首选,由于肾素血管紧张素受体抑制剂的潜在致畸性不建议早期使用。单纯子痫前期患者可给予期待治疗,包括降压、对症和营养支持等。妊娠期高血压疾病通常在分娩12周内自发缓解,如持续存在,应诊断慢性高血压,特别是分娩6个月后仍有蛋白尿的患者,建议行肾活检明确是否患有慢性肾脏疾病。

Hypertensive disorders in pregnancy (HDP) is a common and serious clinical syndrome, characterized by hypertension, renal injury, and neurological symptoms in pregnancy, and is a major cause for maternal death. According to 2013 ACOG (American College of Obstetricians and Gynecologists) guideline, HDP is categorized as gestational hypertension, preeclamsia-eclamsia, chronic hypertension, and chronic hypertension complicated with preeclamsia. Patients with blood pressure of ≥160/110 mmHg need antihypertensive therapy of which the first-line drugs are calcium channel blockers and adrenoceptor blocking agents. Renin and angiotensin receptor blockers are contraindicated in the first trimester of pregnancy due to their potential teratogenicity. Patients with mild preeclampsia are suggested to receive expectant management, including antihypertensive medication, symptomatic treatment, and nutritional supportive treatment. HDP has a tendency to spontaneous remission within 12 weeks after delivery. Diagnosis of chronic hypertension is considered if hypertension persists. Renal biopsy should be advised to investigate the underlying chronic kidney disease if proteinuria persists more than six months after delivery.

表1 妊娠期高血压疾病诊断标准
表2 妊娠期高血压疾病患者降压药物的使用方法及不良反应
表3 妊娠期高血压疾病并发急性肾损伤的治疗方案
[1]
Ye C, Ruan Y, Zou L, et al. The 2011 survey on hypertensive disorders of pregnancy (HDP) in China: prevalence, risk factors, complications, pregnancy and perinatal outcomes [J]. PLoS One, 2014, 9(6): e100180.
[2]
Arulkumaran N, Lightstone L. Severe pre-eclampsia and hypertensive crises [J]. Best Pract Res Clin Obstet Gynaecol, 2013, 27(6): 877-884.
[3]
Schneider S, Freerksen N, Maul H, et al. Risk groups and maternal-neonatal complications of preeclampsia - Current results from the national German Perinatal Quality Registry [J]. J Perinat Med, 2011, 39 (3): 257-265.
[4]
Chaiworapongsa T, Chaemsaithong P, Yeo L, et al. Pre-eclampsia part 1: current understanding of its pathophysiology [J]. Nat Rev Nephrol, 2014, 10(8): 466-480.
[5]
American College of Obstetricians and Gynecologists, Task Force on Hypertension in Pregnancy. Hypertension in pregnancy: report of the American College of Obstetricians and Gynecologists′ Task Force on Hypertension in Pregnancy [J]. Obstet Gynecol, 2013, 122(5): 1122-1131.
[6]
Livingston JC, Livingston LW, Ramsey R, et al. Magnesium sulfate in women with mild preeclampsia: a randomized controlled trial [J]. Obstet Gynecol, 2003, 101(2): 217-220.
[7]
Leeman M. Arterial hypertension in pregnancy [J]. Rev Med Brux, 2008, 29(4): 340-345.
[8]
Chaiworapongsa T, Chaemsaithong P, Steven J, et al. Pre-eclampsia part 2: prediction, prevention and management [J]. Nat Rev Nephrol, 2014, 10(9): 531-540.
[9]
Duley L, Henderson-Smart D J. Drugs for treatment of very high blood pressure during pregnancy [J]. Cochrane Database Syst Rev, 2002, 4: CD001449.
[10]
Rosenthal T, Oparil S. The effect of antihypertensive drugs on the fetus [J]. J Hum Hypertens, 2002, 16(5): 293-298.
[11]
Vikse BE, Irgens LM, Leivestad T, et al. Preeclampsia and the risk of end-stage renal disease [J]. N Engl J Med, 2008, 359(8): 800-809.
[12]
Wei Q, Zhang L, Liu X. Outcome of severe preeclampsia manifested as nephrotic syndrome [J]. Arch Gynecol Obstet, 2011, 283(2): 201-204.
[13]
Stratta P, Besso L, Canavese C, et al. Is pregnancy-related acute renal failure a disappearing clinical entity [J]? Renal failure, 1996, 18(4): 575-584.
[14]
Fakhouri F, Vercel C, Frémeaux-Bacchi V. Obstetric nephrology: AKI and thrombotic microangiopathies in pregnancy [J]. Clin J Am Soc Nephrol, 2012, 7(12): 2100-2106.
[15]
Nwoko R, Plecas D, Garovic V D. Acute kidney injury in the pregnant patient [J]. Clin Nephrol, 2012, 78(6): 478-486.
[16]
Prakash J, Niwas SS, Parekh A, et al. Acute kidney injury in late pregnancy in developing countries [J]. Renal failure, 2010, 32(3): 309-313.
[17]
刘力生.中国高血压防治指南2010[J]. 中华高血压杂志,2011, 19(8): 701-708.
[18]
Snydal S. Major changes in diagnosis and management of preeclampsia [J]. J Midwifery Womens Health, 2014, 59(6): 596-605.
[19]
van der Graaf AM, Toering TJ, Faas MM, et al. From preeclampsia to renal disease: a role of angiogenic factors and the renin-angiotensin aldosterone system [J]? Nephrol Dial Transplant, 2012, 27(Suppl 3): iii51-iii57.
[20]
Anderson UD, Olsson MG, Kristensen KH, et al. Review: Biochemical markers to predict preeclampsia [J]. Placenta, 2012, 33(Suppl): S42-S47.
[21]
Hofmeyr GJ, Belizán JM, von Dadelszen P, et al. Low-dose calcium supplementation for preventing preeclampsia: a systematic review and commentary [J]. BJOG, 2014, 121(8): 951-957.
[22]
Poprawski G, Wender-Ozegowska E, Zawiejska A, et al. Modern methods of early screening for preeclampsia and pregnancy-induced hypertension--a review [J]. Ginekol Pol, 2012, 83(9): 688-693.
[1] 史学兵, 谢迎东, 谢霓, 徐超丽, 杨斌, 孙帼. 声辐射力弹性成像对不可切除肝细胞癌门静脉癌栓患者放射治疗效果的评价[J/OL]. 中华医学超声杂志(电子版), 2024, 21(08): 778-784.
[2] 李钱梅, 何冠南, 赵婧, 陈曦, 唐玉英, 马丽琼, 梁蓉, 袁桃, 李明星. 早孕期低危妊娠和高危妊娠胎盘微血流成像特征及预后分析[J/OL]. 中华医学超声杂志(电子版), 2024, 21(07): 726-732.
[3] 曹琮沅, 黄烁金, 何倩婷, 王安训. 平阳霉素复合剂治疗口腔颌面部脉管畸形的有效性和安全性[J/OL]. 中华口腔医学研究杂志(电子版), 2024, 18(06): 368-374.
[4] 李华志, 曹广, 刘殿刚, 张雅静. 不同入路下行肝切除术治疗原发性肝细胞癌的临床对比[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 52-55.
[5] 陈浩, 王萌. 胃印戒细胞癌的临床病理特征及治疗选择的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 108-111.
[6] 梁孟杰, 朱欢欢, 王行舟, 江航, 艾世超, 孙锋, 宋鹏, 王萌, 刘颂, 夏雪峰, 杜峻峰, 傅双, 陆晓峰, 沈晓菲, 管文贤. 联合免疫治疗的胃癌转化治疗患者预后及术后并发症分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 619-623.
[7] 许月芳, 刘旺, 曾妙甜, 郭宇姝. 多粘菌素B和多粘菌素E治疗外科多重耐药菌感染临床疗效及安全性分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 700-703.
[8] 刘柏隆, 周祥福. 压力性尿失禁阶梯治疗的项目介绍[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(01): 125-125.
[9] 刘柏隆. 女性压力性尿失禁阶梯治疗之手术治疗方案选择[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(01): 126-126.
[10] 中华医学会器官移植学分会. 肝移植术后缺血性胆道病变诊断与治疗中国实践指南[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 739-748.
[11] 陈伟杰, 何小东. 胆囊癌免疫靶向治疗进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 763-768.
[12] 崔军威, 蔡华丽, 胡艺冰, 胡慧. 亚甲蓝联合金属定位夹及定位钩针标记在乳腺癌辅助化疗后评估腋窝转移淋巴结的临床应用价值探究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 625-632.
[13] 王誉英, 刘世伟, 王睿, 曾娅玲, 涂禧慧, 张蒲蓉. 老年乳腺癌新辅助治疗病理完全缓解的预测因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 641-646.
[14] 张平骥, 徐钰, 李天水, 庞文翼, 符师宁, 张梦圆. 重症患者镇静治疗现状及期望的调查研究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 562-567.
[15] 王昌前, 林婷婷, 宁雨露, 王颖杰, 谭文勇. 光免疫治疗在肿瘤领域的临床应用新进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 575-583.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?